After percutaneous coronary intervention with drug-eluting stents, 12 months of dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor became dogma. The DAPT trial (2014) tested extending this to 30 months, finding reduced stent thrombosis (0.4% vs 1.4%) but increased bleeding. This raised the fundamental question: is 12 months too long for some patients and too short for others?

DAPT Study2014Landmark

Stent thrombosis: 0.4% vs 1.4% (p<0.001); major bleeding increased with longer DAPT

NEJMRCTN=9,961

Proof

Landmark RCTs and pivotal trials that established the evidence base

A wave of trials explored shorter DAPT durations. STOPDAPT-2 (2019) showed 1-month DAPT followed by clopidogrel monotherapy was superior to 12-month DAPT. TWILIGHT (2019) demonstrated that dropping aspirin after 3 months and continuing ticagrelor monotherapy reduced bleeding by 44% without increasing ischaemic events. TICO (2020) confirmed this with a 34% reduction in net adverse clinical events with ticagrelor monotherapy after 3 months.

STOPDAPT-22019Landmark

Net adverse clinical events: 2.4% vs 3.7% (p=0.04) favouring 1-month DAPT

JAMARCTN=3,045

TWILIGHT2020Landmark

BARC 2, 3, or 5 bleeding: HR 0.56 (95% CI 0.45–0.68), p<0.001 favouring ticagrelor monotherapy

European heart journalRCTN=7,119

TICO2020Landmark

Net adverse clinical events: HR 0.66 (95% CI 0.48–0.92) favouring ticagrelor monotherapy

JAMARCTN=3,056

Extension

Follow-up studies, subgroup analyses, and real-world validation

MASTER DAPT (2021) addressed high-bleeding-risk patients specifically, showing that abbreviated DAPT (approximately 1 month) followed by single antiplatelet therapy was non-inferior to standard DAPT for ischaemic events and superior for bleeding reduction. This consolidated the trend toward personalised, risk-stratified DAPT duration rather than a one-size-fits-all approach.

MASTER DAPT2021Landmark

Bleeding: HR 0.68 (95% CI 0.56–0.83) favouring abbreviated DAPT

NEJMRCTN=4,579

Now

Current standard of care and ongoing research directions

The field has moved from rigid 12-month DAPT to personalised strategies guided by ischaemic and bleeding risk. P2Y12 monotherapy (dropping aspirin) after 1-3 months of DAPT is increasingly adopted for many patients. Current research explores aspirin-free strategies from the outset and integration with risk scores (DAPT, PRECISE-DAPT) for individual tailoring.

Landmark Trials in This Story

DAPT Study2014Landmark

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents

Stent thrombosis: 0.4% vs 1.4% (p<0.001); major bleeding increased with longer DAPT

NEJMRCTN=9,961

STOPDAPT-22019Landmark

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial

Net adverse clinical events: 2.4% vs 3.7% (p=0.04) favouring 1-month DAPT

JAMARCTN=3,045

TWILIGHT2020Landmark

Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS

BARC 2, 3, or 5 bleeding: HR 0.56 (95% CI 0.45–0.68), p<0.001 favouring ticagrelor monotherapy

European heart journalRCTN=7,119

TICO2020Landmark

Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial

Net adverse clinical events: HR 0.66 (95% CI 0.48–0.92) favouring ticagrelor monotherapy

JAMARCTN=3,056

MASTER DAPT2021Landmark

Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk

Bleeding: HR 0.68 (95% CI 0.56–0.83) favouring abbreviated DAPT

NEJMRCTN=4,579

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3M+ peer-reviewed articles.

Ask about this topic Try AttendMe Free

Related Evidence

Hematology

VTE Anticoagulation Duration

Who needs lifelong treatment?

Anesthesiology

Perioperative Anticoagulation Bridging

The end of bridge-everything

Radiology

Breast Screening Modalities

Beyond mammography

Rheumatology

RA Treatment Strategy

Treat-to-target transforms outcomes

Frequently Asked Questions

How long should dual antiplatelet therapy last after a stent?+

The answer has evolved from a fixed 12-month standard to a personalised approach. Trials like TWILIGHT, TICO, and STOPDAPT-2 showed that 1-3 months of DAPT followed by P2Y12 monotherapy reduces bleeding without increasing ischaemic events in many patients. Duration is now guided by individual bleeding and ischaemic risk.

What is P2Y12 monotherapy after PCI?+

P2Y12 monotherapy means dropping aspirin after a short period of DAPT (typically 1-3 months) and continuing with a P2Y12 inhibitor (usually ticagrelor or clopidogrel) alone. The TWILIGHT trial showed this reduces bleeding by 44% compared to continued DAPT.